Treatment Trials
Below is a listing of the current treatment clinical trials for cancer offered through the Genesis Cancer Care Institute and Iowa Cancer Care Specialists. See clinical trials offered by Hematology-Oncology Associates of the Quad-Cities, PC. These available trials are listed by cancer type.
For a complete description of a particular clinical trial, go to the CancerTrials search page (click on Advanced Search). Complete the first five areas on the form: naming the type of cancer; stage/subtype of cancer (all); type of trial (treatment); status of trial (active); and the protocol ID as listed below. Once this information is entered click on the search button at the bottom of the page. You will then get a page listing the trial by title. Click on the title and you will have further information to read and print out as you wish. If you need assistance with this process, contact us.
Breast Cancer
NSABP B-37: A Randomized Clinical Trial of Adjuvant Chemotherapy for Radically Resected Loco-Regional Relapse of Breast Cancer
NSABP B-39: A Randomized Phase III Study of Conventional Whole Breast Irradiation (WBI) vs Partial Breast Irradiation (PBI) for Women With Stage 0, I or II Breast Cancer (Partial Closure)
NSABP B-41: Randomized Phase III Trial of Neoadjuvant Therapy for Patients With Palpable and Operable HER2-Positive Breast Cancer Comparing the Combination of Trastuzumab Plus Lapatinib to Trastuzumab and to Lapatinib Administered With Weekly Paclitaxel Following AC Accompanied by Correlative Science Studies to Identify Predictors of Pathologic Complete Response
NSABP B-42: Clinical Trial to Determine the Efficacy of 5 Years of Letrozole Compared to Placebo in Patients Completing 5 Years of Hormonal Therapy Consisting of an Aromatase Inhibitor (AI) or Tamoxifen Followed by an AI in Prolonging Disease-Free Survival in Postmenpausal Women With Hormone Receptor Positive Cancer
NSABP B-43: A Phase III Clinical Trial Comparing Trastuzumab Given Concurrently with Radiation Therapy and Radiation Therapy Alone for Women With HER2-Positive Ductal Carcinoma In Situ Resected by Lumpectomy
NSABP B-44 (Industry): The BETH trial--Bevacizumab With Trastuzumab Adjuvant Therapy in HER2 (+) Breast Cancer
SWOG S0221: Phase III Trial of Continuous Schedule AC + G vs Q 2 Week Schedule AC, Followed by Paclitaxel Given Either Every 2 Weeks or Weekly for 12 Weeks as Post-Operative Adjuvant Therapy in Node-Positive or High-Risk Node-Negative Breast Cancer
SWOG S0226: Phase III Randomized Trial of Anastrozole vs Anastrozole and Fulvestrant as First-Line Therapy for Post Menopausal Women With Metasatic Breast Cancer
SWOG S0622: Phase II Studies of Two Different Schedules of Dasatinib in Bone Metastasis Predominant Metastatic Breast Cancer
ECOG E1105: Randomized Phase III Double-Blind, Placebo-Controlled Trial of First-Line Chemotherapy and Trastuzumab With or Without Bevacizumab for Patients with HER-2/NEU Over-Expressing Metastatic Breast Cancer
ECOG E5103: Double-Blind Phase III Trial of Doxorubicin/Cyclophosphamide Followed by Paclitaxel With Bevacizumab or Placebo in Patients With Lymph Node (+) and High Risk Lymph Node (-) Breast Cancer
CALGB 40101: Cyclophosphamide and Doxorubicin (CA) (4 vs 6 cycles) vs Paclitaxel (4 vs 6 cycles) as Adjuvant Therapy for Women with Node Negative Breast Cancer: A 2X2 Factorial Randomized Study
CALGB 40302: Endocrine Therapy With or Without Inhibition of EGF and HER2 Growth Factor Receptors: A Randomized Double Blind, Placebo-Controlled Phase III Trial of Fulvestrant With or Without Lapatinib for Postmenopausal Women With Hormone Receptor Positive Advanced Breast Cancer
CALGB 40502: A Randomized Phase III Trial of Weekly Paclitaxel Compared to Weekly Nanoparticle Albumin Bound Nab-Paclitaxel or Ixabepilone Combined With Bevacizumab as First-Line Therapy for Locally Recurrent or Metastatic Breast Cancer
CALGB 70301: Quality of Life, Employment and Informal Care Cost Analysis in Women Receiving Adjuvant Chemotherapy for Node-Negative Breast Cancer (Companion Study to CTSU 40101)
IBCSG 2402: Suppression of Ovarian Function Trial (SOFT)
NCCTG N0733: Phase II Trial of Capecitabine and Lapatinib With or Without IMC-A12 in Patients With HER2 (+) Breast Cancer Previously Treated With Trastuzumab and an Anthracycline and/or a Taxane
ECOG PACCT-1 (Program for the Assessment of Clinical Cancer Tests): Trial assigning Individualized Options for Treatment
back to top
Carcinoid Tumor
SWOG S0518: Phase III Prospective Randomized Comparison of Depot Octreotide + Interferon Alpha vs Depot Octreotide + Bevacizumab in Advanced, Poor Prognosis Carcinoid Patients
back to top
Gastro-Intestinal (Colon Cancer; Rectal Cancer; Gastrointestional Stromal Tumor)
ECOG E5202: Randomized Phase III Study Comparing 5-FU, Leucovorin and OXAL vs 5-FU, Leucovorin, OXAL and Bevacizumab in Patients With Stage II Colon Cancer at High Risk for Recurrence to Determine Prospectively the Prognostic Value of Molecular Markers
ECOG E5204: Intergroup Randomized Phase III Study of Postoperative Oxaliplatin, 5-FU, and Leucovorin vs Oxaliplatin, 5-FU, Leucovorin and Bevacizumab for Patients With Stage II or III Rectal Cancer Receiving Preoperative Chemoradiation
CALGB C80405: A Phase III Trial of Irinotecan/5-FU/Leucovorin or Oxaliplatin/5-FU/Leucovorin With Bevacizumab or Cetuximab or With the Combination of Bevacizumab and Cetuximab for Patients With Untreated Metastatic Adenocarcinoma of the Colon or Rectum
CTSU NCCTG N0147: Randomized Phase III Trial of Irinotecan (CPT-11) and/or Oxaliplatin Plus 5-FU/ Leucovorin With or Without Cetuximab (C225) After Curative Resection for Patients With Stage III Colon Cancer (Closed to patients age 70 or older)
NSABP R-04: Treatment With Two Chemotherapy Drugs Combined With Radiation Therapy for Patients With Rectal Cancer
SWOG S0502: A Phase III Randomized Trial of Imatinib, With or Without Bevacizumab, in Patients With Metastatic or Unresectable Gastrointestinal Stromal Tumors
back to top
Genito-Urinary (Prostate; Kidney)
3410: A Prospective Randomized Phase III Trial Comparing Consolidation Therapy With or Without Strontium-89 (SR 89) Following Induction Chemotherapy in Androgen-Independent Prostate Cancer
CTSU 90203: Randomized Phase III Study of Neo-Adjuvant Docetaxel and Androgen Deprivation Prior to Radical Prostatectomy vs Immediate Radical Prostatectomy in Patients With High-Risk, Clinically Localized Prostate Cancer
ECOG E2804: The BeST Trial, A Randomized Phase II Study of VEGF, RAF kinase and mTOR Combination Targeted Therapy (CTT) with Bevacizumab, Sorafenib and Temsirolimus in Advanced Renal Cell Carcinoma
ECOG E2805: Randomized, Double-Blind Phase III Trial of Adjuvant Sunitinib vs Sorafenib vs Placebo in Patients With Resected Renal Cell Cancer
SWOG S0421: Phase III Study of Docetaxel and Atrasentan vs Docetaxel and Placebo for Patients with Advanced Hormone Refractory Prostate Cancer
back to top
GYNECOLOGY (Endometrial; Ovarian Epithelial)
GOG-0209: Randomized Phase III Trial of Doxorubicin/Cisplatin/Paclitaxel and G-CSF vs Carboplatin/Paclitaxel in Patients With Stage II and IV or Recurrent Endometrial Cancer (Stratum 2, Prior Radiation Therapy--Temporarily Closed)
GOG-0218: Phase III Trial of Carboplatin and Paclitaxel + Placebo vs Carboplatin and Paclitaxel + Concurrent Bevacizumab Followed by Placebo vs Carboplatin and Paclitaxel + Concurrent and Extended Bevacizumab in Women With Newly Diagnosed, Previously Untreated, Suboptimal Advanced Stage Epithelial Ovarian, Primary Peritoneal Cancer or Fallopian Tube Cancer
back to top
Head & Neck
back to top
Leukemia (Acute Myeloid (AML) Adult; Chronic Lymphocytic (CLL))
SWOG 9007: Cytogenic Studies in Leukemia Patients (not available on CancerTrials search)
SWOG S9910: Leukemia Centralized Reference Lab and Tissue Repositories-Consent to Perform Cellular and Molecular Studies in Leukemia Patients
SWOG S0106: Phase III Study of the Addition of Gemtuzumab Ozogamicin (Mylotarg®) During Induction Therapy vs Standard Induction With Daunomycin and Cytosine Arabinoside Followed by Consolidation and Subsequent Randomization to Post-Consolidation Therapy With Gemtuzumab Ozogamicin (Mylotarg®) or No Additional Therapy for Patients Under Age 61 With Previously Untreated De Novo Acute Myeloid Leukemia
CALGB 10501: Phase III Intergroup CLL Study of Asymptomatic Patients with Untreated Chronic Lymphocytic Leukemia Patients Randomized to Early Intervention vs Observation With Later Treatment in the High-Risk Genetic Subset with IgVh Unmutated Disease
ECOG E2902: Phase III Randomized Study of Farnesyl Transferase Inhibitor R115777 in Acute Myeloid Leukemia (AML) Patients in Second or Subsequent Remission or in Remission after Primary Induction Failure
back to top
Lung (Non-Small Cell)
SWOG S9925: Lung Cancer Specimen Repository Protocol, Ancillary
SWOG E5597: Phase III Chemoprevention Trial of Selenium Supplementation in Persons With Resected Stage I Non-Small Cell Lung Cancer
SWOG S0424: Molecular Epidemiology Case-Series of Non-Small Cell Lung Cancer in Smoking and Non-Smoking Women and Men (Female and male smoker strata closed- 7/15/07)
ECOG E1505: Phase III Randomized Trial of Adjuvant Chemotherapy With or Without Bevacizumab for Patients With Completely Resected Stage IB (> 4 cm)-IIIA Non-Small Cell Lung Cancer
NCCTG N0723 MARVEL: Marker Validation of Erlotinib in L ung Cancer - Phase III Biomarker Validation Study of Second-Line Therapy in Patients With Advanced Non-Small Cell Lung Cancer (NSCLC) Randomized to Pemetrexed vs Erlotinib
back to top
Lymphoma
SWOG 8819: Central Lymphoma Repository Tissue Procurement Protocol
SWOG 8947: Central Lymphoma Serum Repository Protocol (not available on CancerTrials search)
SWOG 9245: Central Lymphoma Repository Tissue Procurement Protocol for Relapse or Recurrent Disease
back to top
Melanoma
ECOG E1697: Phase III Randomized Study of Four Weeks High Dose IFN-2b in Stage T2B N0, T3A-B N0, T4A-B N0 and T1-4, N1A, 2A (microscopic) Melanoma
SWOG S0438: A Randomized Phase II Trial of BAY 43-9006 With Either CCI-779 or R115777 in Metastatic Melanoma
back to top
Multiple Myeloma
SWOG S0309: Myeloma Specimen Repository Protocol, Ancillary
ECOG E1A06: An Intergroup Phase III Randomized Controlled Trial Comparing Melphalan, Prednisone and Thalidomide vs Melphalan, Prednisone and Lenalidomide in Newly Diagnosed Myeloma Patients Who Are Not Candidates for High-Dose Therapy
back to top
